Please try another search
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Charles V. Baltic | 62 | 2011 | Independent Non-Executive Chair |
Thomas C. Reynolds | 64 | 2013 | Independent Non-Executive Director |
Nicholas R. Glover | 54 | 2013 | Independent Non-Executive Director |
Frederick W. Driscoll | 72 | 2018 | Independent Non-Executive Director |
David M. Urso | 59 | 2014 | CEO, President & Director |
Taheer Datoo | - | 2023 | Director |
Steven Duncan Wood | 41 | 2023 | Independent Non-Executive Director |
James P. Flynn | 43 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review